These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31406692)

  • 1. A meningococcal B vaccine induces cross-protection against gonorrhea.
    Azze RFO
    Clin Exp Vaccine Res; 2019 Jul; 8(2):110-115. PubMed ID: 31406692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
    Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O
    Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.
    Sierra-González VG
    MEDICC Rev; 2019 Oct; 21(4):19-27. PubMed ID: 32335565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
    Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
    MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protection induced by VA-MENGOC-BC® vaccine.
    Ochoa-Azze RF
    Hum Vaccin Immunother; 2018 May; 14(5):1064-1068. PubMed ID: 29420119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
    Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
    PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of meningococcal group B OMV vaccines, beyond their brief.
    Petousis-Harris H
    Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into Prevention of Neisseria Gonorrhoeae: A Short Review.
    La Fauci V; Lo Giudice D; Squeri R; Genovese C
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423044
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
    Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
    Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
    Semchenko EA; Tan A; Borrow R; Seib KL
    Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meningococcal disease and VA-MENGOC BC in minors less than 1 year of age. Cuba, 1983 to 1991].
    Rico Cordeiro O; Jiménez Barreras R; Pereira Colls C
    Rev Cubana Med Trop; 1996; 48(1):34-9. PubMed ID: 9768267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characterization of Neisseria meningitidis strains isolated from carriers in Cuba during 20 years].
    Martínez Motas I; Sierra González G; Núñez Gutiérrez N; Izquierdo Pérez L; Climent Ruíz Y; Mirabal Sosa M
    Rev Cubana Med Trop; 2006; 58(2):124-33. PubMed ID: 23427430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway.
    Whelan J; Kløvstad H; Haugen IL; Holle MR; Storsaeter J
    Emerg Infect Dis; 2016 Jun; 22(6):1137-9. PubMed ID: 27191543
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploitation of
    Petousis-Harris H; Radcliff FJ
    Front Immunol; 2019; 10():683. PubMed ID: 31024540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates.
    Sifontes S; Infante JF; Pérez P; Caro E; Sierra G; Campa C
    Arch Med Res; 1997; 28(1):41-5. PubMed ID: 9078586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba.
    Climent Y; Yero D; Martinez I; Martín A; Jolley KA; Sotolongo F; Maiden MC; Urwin R; Pajón R
    J Clin Microbiol; 2010 Mar; 48(3):802-10. PubMed ID: 20042619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
    Masforrol Y; Gil J; García D; Noda J; Ramos Y; Betancourt L; Guirola O; González S; Acevedo B; Besada V; Reyes O; González LJ
    Hum Vaccin Immunother; 2017 Nov; 13(11):2548-2560. PubMed ID: 29083947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.